Tag: Nasdaq:SKYX

SKYX Pre-Announces Record Second Quarter 2025 Revenues of $23.1 Million Compared to First Quarter Revenues of $20.1 Million, as it Continues to Grow Market...

SKYX Pre-Announces Record Second Quarter 2025 Revenues of $23.1 Million Compared to First Quarter Revenues of $20.1 Million, as it Continues to Grow Market

SKYX Provides Corporate Update, Including its Official Addition to the Russell 2000 on June 27, 2025, and its Expected Deployment of 500,000 Units of...

SKYX Provides Corporate Update

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Comments

This field is for validation purposes and should be left unchanged.

HomeTagsNasdaq:SKYX

Lilly’s Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with...

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

TAIWAN DESIGN POWER Debuts at Busan Design Festival, Showcasing Taiwan’s Design Innovation and Creative Value

Tag: Nasdaq:SKYX

SKYX Pre-Announces Record Second Quarter 2025 Revenues of $23.1 Million Compared to First Quarter Revenues of $20.1 Million, as it Continues to Grow Market...

SKYX Provides Corporate Update, Including its Official Addition to the Russell 2000 on June 27, 2025, and its Expected Deployment of 500,000 Units of...

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us